{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:57:08Z","timestamp":1790647028324,"version":"4.1.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T00:00:00Z","timestamp":1584057600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Despite improvements in first-line treatment of T-cell acute lymphoblastic leukemia (T-ALL), the outcome of relapsed T-ALL remains dismal with less than 7% achieving a long-term survival. Thus, there is an unmet need for new treatment strategies to improve outcomes in this setting. Suppression of apoptosis is one of the hallmarks of anticancer drug resistance. Hence, over the past few years, antiapoptotic proteins have become an attractive target for therapeutic intervention in several hematologic malignancies. Venetoclax (ABT-199) is a novel, orally bioavailable small-molecule inhibitor of B-cell lymphoma 2 (BCL-2), a key regulator of the intrinsic apoptotic pathway. Recent preclinical studies have suggested that inhibition of BCL-2 may be a novel therapeutic strategy for patients with T-ALL. Herein, we report a case of clinical response to venetoclax in combination with a hypomethylating agent in a patient with relapsed T-ALL after allogeneic stem cell transplant and review the existing literature.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.hemonc.2019.10.002","type":"journal-article","created":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T22:42:42Z","timestamp":1584571362000},"page":"246-251","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":42,"title":["Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia"],"prefix":"10.4103","volume":"14","author":[{"given":"Nosha","family":"Farhadfar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William S.","family":"May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn Brooke","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20241211","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2011-04-347872","article-title":"Acute leukemia incidence and patient survival among children and adults in the United States, 2001\u20132007","volume":"119","author":"Dores","year":"2012","journal-title":"Blood"},{"key":"R2-10-20241211","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2009-08-231217","article-title":"T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII\/ ECOG 2993)","volume":"114","author":"Marks","year":"2009","journal-title":"Blood"},{"key":"R3-10-20241211","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1002\/cncr.20668","article-title":"Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexametha-sone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"101","author":"Kantarjian","year":"2004","journal-title":"Cancer"},{"key":"R4-10-20241211","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"key":"R5-10-20241211","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2006-11-056754","article-title":"Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801","volume":"109","author":"DeAngelo","year":"2007","journal-title":"Blood"},{"key":"R6-10-20241211","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"R7-10-20241211","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med"},{"key":"R8-10-20241211","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1182\/blood.2018882555","article-title":"Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables","volume":"134","author":"Roberts","year":"2019","journal-title":"Blood"},{"key":"R9-10-20241211","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"R10-10-20241211","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1182\/blood-2014-05-574566","article-title":"ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia","volume":"124","author":"Peirs","year":"2014","journal-title":"Blood"},{"key":"R11-10-20241211","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ccr.2006.10.006","article-title":"Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia","volume":"10","author":"Konopleva","year":"2006","journal-title":"Cancer Cell"},{"key":"R12-10-20241211","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.molcel.2016.02.019","article-title":"Mitochondriajudges and executioners of cell death sentences","volume":"61","author":"Bhola","year":"2016","journal-title":"Mol Cell"},{"key":"R13-10-20241211","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1182\/blood-2007-06-098012","article-title":"BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia","volume":"111","author":"Moore","year":"2008","journal-title":"Blood"},{"key":"R14-10-20241211","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","article-title":"Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199","volume":"4","author":"Chonghaile","year":"2014","journal-title":"CancerDiscov"},{"key":"R15-10-20241211","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.3109\/10428194.2015.1030638","article-title":"A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia","volume":"56","author":"Kipps","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"R16-10-20241211","doi-asserted-by":"crossref","first-page":"7145","DOI":"10.1182\/blood-2011-03-344812","article-title":"BCL2\/BCL-X(L) inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation","volume":"117","author":"Vogler","year":"2011","journal-title":"Blood"},{"key":"R17-10-20241211","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"key":"R18-10-20241211","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41375-018-0201-2","article-title":"The MCL1-specific inhibitor S63845 acts synergistically with venetoclax\/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells","volume":"33","author":"Li","year":"2018","journal-title":"Leukemia"},{"key":"R19-10-20241211","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1016\/j.clml.2018.07.016","article-title":"Safety and efficacy of the BCL inhibitors venetoclax and navitoclax incombination with chemotherapy in patients with relapsed\/refractory acutelymphoblastic leukemia and lymphoblastic lymphom","volume":"18","author":"Hantel","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R20-10-20241211","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/bjh.13050","article-title":"Safety and clinical activity of 5-aza-2\u2032-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed\/refractory acute lymphocytic leukaemia","volume":"167","author":"Benton","year":"2014","journal-title":"Br J Haematol"},{"key":"R21-10-20241211","first-page":"693","article-title":"Decitabine for relapsed acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation","volume":"37","author":"Cui","year":"2017","journal-title":"J Huazhong Univ Sci Technol Med Sci"},{"key":"R22-10-20241211","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/leu.2014.44","article-title":"BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies","volume":"28","author":"Bogenberger","year":"2014","journal-title":"Leukemia"},{"key":"R23-10-20241211","first-page":"216","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"LancetOncol"},{"key":"R24-10-20241211","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","article-title":"Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments","volume":"39","author":"Agarwal","year":"2017","journal-title":"Clin Ther"},{"key":"R25-10-20241211","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1016\/j.clml.2018.07.289","article-title":"Feasibility of the combination of venetoclax and asparaginase-based chemotherapy for adult patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"18","author":"El-Cheikh","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R26-10-20241211","first-page":"6092646","article-title":"Venetoclax in Combination with decitabine for relapsed T-cell acute lymphoblastic leukemia after allogeneic hematopoietic cell transplant","volume":"2018","author":"Rahmat","year":"2018","journal-title":"Case Rep Hematol"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387620300315?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387620300315?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/10.1016\/j.hemonc.2019.10.002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:50:22Z","timestamp":1787838622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1016\/j.hemonc.2019.10.002"}},"subtitle":["A case report and review of literature"],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1016\/j.hemonc.2019.10.002","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}